Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Hush money trial: Trump witness Costello back on the stand after admonishment
NEW YORK (AP) — A defense witness in Donald Trump’s hush money case whom the judge threatened to rem2024-05-222023 Beijing Cultural Forum Arts gala was held to inheriting excellent culture
Beijing, September15 (Youth.cn) -On the evening of September 14th, 2023, the 2023 Beijing Cultural F2024-05-22- A scene from the TV series All the Way to the Sunfeatures actress Li Landi and actor Wang Yang, resp2024-05-22
- FRANKFURT, Germany (AP) — The alleged leaders of a suspected far-right plot to topple the German gov2024-05-22
- Faces of Time showcases Western portraiture in Beijing. LIN QI/CHINA DAILYFine examples of Western p2024-05-22
atest comment